TRXC - TransEnterix, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD

TransEnterix, Inc.

635 Davis Drive
Suite 300
Morrisville, NC 27560
United States

IndustryMedical Devices
Full Time Employees174

Key Executives

NameTitlePayExercisedYear Born
Mr. Anthony FernandoPres, CEO & Director508.93kN/A1972
Mr. Todd M. PopeSr. Advisor839.13k2.02M1965
Mr. Joseph P. Slattery CPA, CPAConsultant515.23k1.97M1965
Mr. Eric A. SmithChief Commercial Officer370.53kN/A1972
Mr. Brett FarabaughInterim Chief Financial OfficerN/AN/A1968
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


TransEnterix, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe. It also provides SurgiBot System, a single-port system robotically enhanced laparoscopic surgical platform. TransEnterix, Inc. is headquartered in Morrisville, North Carolina.

Corporate Governance

TransEnterix, Inc.’s ISS Governance QualityScore as of December 2, 2019 is 7. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 2; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.